首页SSSGY • OTCMKTS
add
赛多利斯
市场资讯
财务信息
损益表
收入
净收入
| (EUR) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 7.94亿 | -2.11% |
经营支出 | 2.77亿 | 5.45% |
净收入 | 1420.00万 | -4.70% |
净利润率 | 1.79 | -2.72% |
每股收益 | 0.87 | -17.92% |
息税折旧摊销前利润 | 1.70亿 | -6.56% |
有效税率 | 26.95% | — |
资产负债表
总资产
负债总额
| (EUR) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 5.79亿 | 97.07% |
总资产 | 97.94亿 | -1.67% |
负债总额 | 60.17亿 | -16.62% |
权益总额 | 37.77亿 | — |
发行在外的股份 | — | — |
市净率 | — | — |
资产回报率 | 1.73% | — |
资本回报率 | 2.04% | — |
现金流
现金净变动
| (EUR) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | 1420.00万 | -4.70% |
来自运营的现金 | 2.66亿 | 47.92% |
投资现金 | -9350.00万 | 96.05% |
融资现金 | -1.86亿 | -108.01% |
现金净变动 | -1200.00万 | -109.11% |
自由现金流 | 1.12亿 | 1,064.33% |
简介
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services. Wikipedia
CEO
成立时间
1870
员工数量
13,762
